{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=19",
    "query": {
      "condition": "Age-Related Macular Degeneration (ARMD)",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 908,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28ARMD%29&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T01:07:56.031Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06388083",
      "title": "A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "STGD1",
        "Stargardt Disease 1"
      ],
      "interventions": [
        {
          "name": "Tinlarebant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Belite Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "12 Years to 20 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-07-31",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06388083"
    },
    {
      "nct_id": "NCT02401945",
      "title": "A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "DE-120",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-04",
      "completion_date": "2016-10-31",
      "has_results": false,
      "last_update_posted_date": "2018-04-18",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02401945"
    },
    {
      "nct_id": "NCT04740931",
      "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema",
        "Central Retinal Vein Occlusion",
        "Hemiretinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 729,
      "start_date": "2021-03-02",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 57,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740931"
    },
    {
      "nct_id": "NCT05791695",
      "title": "A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Intraocular Inflammation",
        "Suspected Endophthalmitis"
      ],
      "interventions": [
        {
          "name": "Non Applicable",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155413,
      "start_date": "2022-09-16",
      "completion_date": "2023-09-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05791695"
    },
    {
      "nct_id": "NCT04627428",
      "title": "Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RPESC-RPE-4W",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Luxa Biotechnology, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-04-05",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Palo Alto, California • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04627428"
    },
    {
      "nct_id": "NCT01397409",
      "title": "Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "AGN-150998",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2011-09-01",
      "completion_date": "2014-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397409"
    },
    {
      "nct_id": "NCT00460967",
      "title": "Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-Related Maculopathy"
      ],
      "interventions": [
        {
          "name": "Rheopheresis",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "OccuLogix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 325,
      "start_date": "2007-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2007-11-07",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00460967"
    },
    {
      "nct_id": "NCT02463344",
      "title": "Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "MA09-hRPE",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Astellas Institute for Regenerative Medicine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-02-25",
      "completion_date": "2019-08-19",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02463344"
    },
    {
      "nct_id": "NCT02247531",
      "title": "A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Lampalizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 975,
      "start_date": "2014-10-06",
      "completion_date": "2018-01-23",
      "has_results": true,
      "last_update_posted_date": "2019-10-15",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02247531"
    },
    {
      "nct_id": "NCT04603937",
      "title": "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "KSI-301",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kodiak Sciences Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 459,
      "start_date": "2020-09-30",
      "completion_date": "2023-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-10-16T01:07:56.031Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603937"
    }
  ]
}